Development

David Lin, Ph. D., is with the Biologics Consulting Group.

Articles

Almost half of pharmaceutical industry profits continue to come from biopharmaceuticals.

Trends Affecting Biopharmaceutical Manufacturing

The European Commission has granted marketing authorization to Incyte and MorphoSys for Minjuvi (tafasitamab) in combination therapy with lenalidomide to treat relapsed or refractory DLBCL.

Incyte and MorphoSys Receive EC Approval for Minjuvi in Combination Therapy for Lymphoma

Aadi Bioscience has closed its previously announced merger with Aerpio Pharmaceuticals and a concurrent $155-million PIPE investment.

Aadi Bioscience and Aerpio Pharmaceuticals Close Merger and $155 Million Private Placement

NGM Biopharmaceuticals has disclosed a fourth antibody drug candidate, NGM831, for development into an oncology therapeutic.

NGM Bio Pinpoints Fourth Antibody Drug Candidate for Oncology Therapy Development

Pfizer’s proposed $2.26-billion acquisition of Trillium Therapeutics will add next-generation hematology-targeted immuno-therapeutics to its oncology pipeline.

Pfizer to Acquire Trillium Therapeutics in $2.26-Billion Deal

Merck KGaA has partnered with Telix Pharmaceuticals to conduct combination clinical studies for cancer therapy.

Merck KGaA and Telix Partner on Pan-Cancer Clinical Combination Studies

A research team at the Keck Graduate Institute will work to adapt its decade-long low-cost vaccine R&D for developing countries into a COVID-19 vaccine.

KGI Team Adapts Vaccine Development Work to Address COVID-19 

FDA has approved AstraZeneca’s Saphnelo, a type I interferon receptor antibody for treating systemic lupus erythematosus.

FDA Approves AstraZeneca’s Lupus mAb, Saphnelo

FDA has accepted Genetech’s BLA for faricimab, a bispecific antibody in development for treating wet age-related macular degeneration and diabetic macular edema.

FDA Accepts Genentech’s Application for Bispecific Antibody to Treat Eye Diseases 

The European Commission has entered into a supply agreement with GlaxoSmithKline and Vir Biotechnology for up to 220,000 doses of sotrovimab, an investigational mAb for treating COVID-19.

Biologics APIs